DOYLESTOWN, PA. - February 17, 2004 - The Quigley Corporation (Nasdaq: QGLY)
reported today that Retroscreen Virology Ltd., under the auspices of Professor
John S. Oxford, will be presenting the results of their recent research on
Quigley's patented formulation and its activity against both the Influenza A
and SARS viruses at the VI International Symposium on Respiratory Viral
Infections between March 18 - 21, 2004 at the Sanibel Harbour Resort & Spa,
Fort Myers, Florida, USA.
Retroscreen, a world leading independent contract
research virology company, specializes in developing anti-viral compounds and
vaccines. Retroscreen has worked with many large pharmaceutical companies to
assist them in developing products that now help to fight viral diseases
worldwide.
The influenza study found that intranasal application by spray of
Quigley Pharma's QR-435 was 100 percent effective in preventing non-infected
ferrets in close proximity to an infected ferret from becoming infected with
the influenza A virus. The ferret is an established animal model for the study
of influenza infection. On the strength of this data, Quigley intends to
initiate a Phase II proof of concept human trial in Europe.
In a second
experiment, in-vitro, Retroscreen Virology Ltd demonstrated that the compound
showed significant virucidal activity against the Urbani strain of the Severe
Acute Respiratory Syndrome (SARS) virus.
About Retroscreen Virology Limited
Retroscreen Virology Limited is an independent research virology company
affiliated with the University of London. Professor John S. Oxford, the firm's
senior scientist, is Professor of Virology at St. Bartholomew's and The Royal
London School of Medicine and Dentistry at the University of London. Dr.
Oxford is the co-author of two standard texts on influenza and virology and has
published more than 250 scientific papers throughout the world. Retroscreen
specializes in developing anti-viral compounds and vaccines, and has worked
with many pharmaceutical companies to assist them in developing products that
now help to fight viral disease worldwide. Additional information is available
on the company's website at www.retroscreen.com.
About Quigley
The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a leading
developer and marketer of diversified health products including the Cold-Eeze®
family of patented zinc gluconate glycine (ZIGG™) lozenges and sugar free
tablets. Cold-Eeze is the only (ZIGG™) lozenge proven in two double-blind
studies to reduce the duration of the common cold from 7.6 to 4.4 days or by
42%. In addition to Over-The-Counter (OTC) products, the company has formed
Quigley Pharma Inc. (http://www.QuigleyPharma.com ), a wholly owned ethical
pharmaceutical subsidiary, to introduce a line of naturally-derived patented
prescription drugs. The Quigley Corporation's customers include leading
national wholesalers and distributors, as well as independent and chain food,
drug and mass merchandise stores and pharmacies.
The Quigley Corporation makes
no representation that the U.S. Food and Drug Administration or any other
regulatory agency will grant an IND or take any other action to allow the
aforementioned products to be studied or marketed. Furthermore, no claim is
made that the potential medicine discussed here is safe, effective, or approved
by the Food and Drug Administration.
Additionally, data that demonstrates activity or effectiveness in animals or in
vitro tests do not necessarily mean that the formula test compound, referenced
herein will be effective in humans. Safety and effectiveness in humans will
have to be demonstrated by means of adequate and well controlled clinical
studies before the clinical significance of the formula test compound is known.
Certain statements in this press release are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995 and
involve known and unknown risk, uncertainties and other factors that may cause
the company's actual performance or achievements to be materially different
from the results, performance or achievements expressed or implied by the
forward-looking statement. Factors that impact such forward-looking statements
include, among others, changes in worldwide general economic conditions,
changes in interest rates, government regulations, and worldwide competition.
